OAM
DARE icon

Oxford Asset Management’s Dare Bioscience DARE Stock Holding History

Oxford Asset Management’s Portfolio DARE Stock Details DARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-339
Closed -$29K – 1405
2016
Q4 		$29K Buy
339
+84
+33% +$8K ﹤0.01% 752
2016
Q3 		$31K Buy
+255
New +$57.1K ﹤0.01% 754

Other funds holding DARE

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oxford Asset Management's DARE Position: Q1 2017 in Review

Oxford Asset Management sold out of Dare Bioscience (DARE) in Q1 2017, closing a stake of 339 shares — an estimated $29K sold.

Oxford Asset Management first reported a position in DARE in Q3 2016 and held it in 2 quarters. The position peaked at $31K in Q3 2016. 27 funds tracked by Wall St. Rank hold DARE as of Q1 2017.

  • Oxford Asset Management reported no remaining Dare Bioscience position as of Q1 2017 after selling out during the quarter.
  • Oxford Asset Management sold 339 Dare Bioscience shares in Q1 2017, an estimated $29K.
  • Oxford Asset Management first reported a position in Dare Bioscience in Q3 2016 and held it in 2 quarters.
  • Oxford Asset Management's Dare Bioscience position peaked at $31K in Q3 2016.
  • 27 funds tracked by Wall St. Rank held Dare Bioscience as of Q1 2017.

Based on Oxford Asset Management's 13F filing for Q1 2017, filed 9 May 2017.